# CSPC Pharmaceutical Group

> CSPC Pharmaceutical Group is a VC fund backing Health Care and Biotechnology. See 5 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Shijiazhuang, China
- Total investments: 5
- Last investment: May 2026
- Lead investor: 0%
- Last updated: Aug 2026
- Website: https://www.cspc.com.hk/

CSPC Pharmaceutical Group is a VC fund in Shijiazhuang focused on Health Care and Biotechnology. CSPC Pharmaceutical Group Limited ("CSPC") is a pharmaceutical group in China. The Company has been listed on the Main Board of the Hong Kong Stock Exchange since 1994. CSPC is a constituent stock of the "Hang Seng Composite Index", "Hang Seng Healthcare Index", "Hang Seng Mainland Healthcare Index","Hang Seng Stock Connect Hong Kong Index" and "Hang Seng China (Hong Kong-listed) 100 Index" and "Hang Seng China Enterprises Index".CSPC has three major business segments including innovative drugs, common generic drugs and bulk drugs. The Group focuses on the manufacturing, researching and marketing of medicines and pharmaceutical related products. The Group has nearly 1,000 finished drugs products including antibiotics, cardio-cerebrovascular drugs, antipyretic analgesic drugs, digestive system drugs, oncology drugs and traditional Chinese medicine. Of which, "NBP", "Oulaining", "Xuanning". "Duomeisu", "Jinyouli" and "Nuolining" are the bestselling innovative drugs products of the Group in China. Bulk drugs products include antibiotics, vitamin C and caffeine series. The manufacturing facilities of CSPC are mainly located in Shijiazhuang City, Hebei Province, China.

## Contacts

5 contacts available for CSPC Pharmaceutical Group. Shizune tracks 2 team members at CSPC Pharmaceutical Group. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/cspc-pharmaceutical-group?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 2 | 40% |
| Biotechnology | 2 | 40% |
| Pharmaceutical | 2 | 40% |
| Medical | 1 | 20% |
| Biopharma | 1 | 20% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 40% |
| Series B | 1 | 20% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Dongchen Cai | Chairman and Chief Executive Officer | 0 | https://shizune.co/investors/profile/dongchen-cai |
| Zhenguo Wang | Vice-Chairman and Rotating Chief Executive Officer | 0 | https://shizune.co/investors/profile/zhenguo-wang |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Degron Therapeutics | Degron Therapeutics is a leading platform company in discovery of molecular glue degraders for cancer treatment. | $40M | Series A | May 14, 2026 |  |
| Yili Pharmaceutical | Yili Pharmaceutical is a pharmaceutical R&D company that mainly engages in biochemical product technology R&D, medical research and experimental development, engineering and technology research and experimental development, and software development. | $14M | Angel | Sep 25, 2025 |  |
| Haihe Biopharma | HaiHe Biopharma is a developer of innovative anti tumor drugs designed to overcome complex diseases and improve pharmacological evaluation. The company focuses on discovery, development and commercialization of innovative anti-tumor drugs, pharmacological efficacy evaluation and provide products including novel topoisomerase I inhibitors and oralc-Met highly selective inhibitors, enabling customers to improve their health conditions and research quality in an efficient manner. | $171M | Series B | Jul 24, 2020 |  |
| Haihe Biopharma | HaiHe Biopharma is a developer of innovative anti tumor drugs designed to overcome complex diseases and improve pharmacological evaluation. The company focuses on discovery, development and commercialization of innovative anti-tumor drugs, pharmacological efficacy evaluation and provide products including novel topoisomerase I inhibitors and oralc-Met highly selective inhibitors, enabling customers to improve their health conditions and research quality in an efficient manner. | $146.6M | Series B | Feb 11, 2019 |  |
| GenFleet Therapeutics | GenFleet Therapeutics is a developer and researcher of molecular pharmaceuticals targeting cancer treatments. The company specializes in developing innovative molecular-level pharmaceuticals and antibody drugs targeting various cancer systems, providing effective medical solutions to reactivate tumor-specific immune responses and to mobilize thebody's own immune system. | $17.3M | Series A | Nov 30, 2018 |  |

5 of 5 investments shown.

## Co-investors
- [BioTrack Capital](https://shizune.co/investors/profile/biotrack-capital) — VC Fund, 2 deals together
- [Yingke Capital](https://shizune.co/investors/profile/yingke-capital) — VC Fund, 2 deals together
- [3H Health Investment](https://shizune.co/investors/profile/3h-health-investment) — VC Fund, 1 deal together
- [ALAN AMC](https://shizune.co/investors/profile/alan-amc) — VC Fund, 1 deal together
- [Ally Bridge Group](https://shizune.co/investors/profile/ally-bridge-group) — VC Fund, 1 deal together
- [Atlas Holdings Group](https://shizune.co/investors/profile/atlas-capital-group) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does CSPC Pharmaceutical Group invest in?

CSPC Pharmaceutical Group invests primarily in Health Care, Biotechnology and Pharmaceutical startups, most often at Series A and Series B stage. Most of the 5 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact CSPC Pharmaceutical Group?

Public channels for CSPC Pharmaceutical Group include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at CSPC Pharmaceutical Group?

The team at CSPC Pharmaceutical Group includes Dongchen Cai (Chairman and Chief Executive Officer) and Zhenguo Wang (Vice-Chairman and Rotating Chief Executive Officer). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co